EHA 2016: When will the daratumumab triplet combination be approved for multiple myeloma?
Antonio Palumbo, MD from the University of Turin, Turin, Italy talks about when daratumumab will be available in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone. Daratu...
Author: VJHemOnc
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: Why daratumumab is effective in multiple myeloma - results from the CASTOR trial
Antonio Palumbo, MD from the University of Turin, Turin, Italy gives an overview of the results of the Phase III CASTOR trial of daratumumab with bortezomib and dexamethasone (NCT02136134). This combi...
Author: VJHemOnc
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
Trial results and drug combinations for bortezomib in multiple myeloma
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium discusses the role of bortezomib in relapsed/refractroy multiple myeloma (MM). Prof Delforge, discusses the various trials...
Author: VJHemOnc
Added: 05/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2016 Category: Cancer & Oncology Source Type: podcasts
History of approvals for proteasome inhibitors bortezomib, carfilzomib and ixazomib
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium provides an overview of the approval of proteasome inhibitors in relapsed/refractory multiple myeloma (MM) since 2003. Pro...
Author: VJHemOnc
Added: 05/23/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 23, 2016 Category: Cancer & Oncology Source Type: podcasts
Transplant vs bortezomib and LEN/DEX in multiple myeloma
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a clinical trial (IFM 2013-04) of bortezomib plus lenalidomide and dexamethasone (LEN/DEX) as the primary treatment for ...
Author: VJHemOnc
Added: 02/10/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 10, 2016 Category: Cancer & Oncology Source Type: podcasts
R-CHOP With or Without Bortezomib Results at ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses R-CHOP With or Without Bortezomib Results at ASH 2015
Author: ASHReport
Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts
Day 2 highlights of the International Workshop on Non-Hodgkin Lymphoma 2015 meeting: Bortezomib, proteasome inhibitor, for B-cell lymphoma
John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, ...
Author: VJHemOnc
Added: 11/18/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 18, 2015 Category: Cancer & Oncology Source Type: podcasts
Does Vitamin C Block Absorption of Myeloma Treatment?
At a recent multiple myeloma town meeting, an audience member wanted to know if vitamin C interferes with the absorption of bortezomib (Velcade). Myeloma expert Dr. Orlowski explains why patients shou...
Author: P2Professional
Added: 10/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - October 11, 2015 Category: Cancer & Oncology Source Type: podcasts
Does Vitamin C Block Absorption of Myeloma Treatment?
At a recent multiple myeloma town meeting, an audience member wanted to know if vitamin C interferes with the absorption of bortezomib (Velcade). Myeloma expert Dr. Orlowski explains why patients shou...
Author: patientpower
Added: 10/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - October 11, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2014: Panorama 1 Phase 3 study of PAN or placebo plus BTZ and Dex in RRMM
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in r...
Author: InternationalMyelomaFoundation
Added: 09/11/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 11, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2014: MM-005 Phase 1 trial of POM, BORT, and LoDEX in LEN refractory and PI exposed myeloma
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomid...
Author: InternationalMyelomaFoundation
Added: 09/11/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 11, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2014: Treatment of RRMM with weekly CyBor-P/D
Donna Reece, MD
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Treatment of relapsed/refractory multiple myeloma with weekly cyclophosphamide plus bortezomib plus prednisone or dexameth...
Author: InternationalMyelomaFoundation
Added: 09/11/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 11, 2015 Category: Cancer & Oncology Source Type: podcasts
ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma | Dr Joseph Mikhael at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of ENDEAVOR, a randomised, open-label, phase 3 tri...
Author: EMJ
Added: 08/26/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 26, 2015 Category: Cancer & Oncology Source Type: podcasts
ASCO 2015: Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma
At ASCO 2015, Dr Joseph Mikhael discusses the results of the ENDEAVOR trial, a phase 3 head-to-head study that demonstrated superiority of carfilzomib over bortezomib in patients with relapsed multipl...
Author: VJHemOnc
Added: 07/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 10, 2015 Category: Cancer & Oncology Source Type: podcasts
Therapy for Newly Diagnosed Mantle Cell Lymphoma
In this video Dr. John Leonard discusses the recent findings from a publication in the New England Journal of Medicine about the efficacy of substituting bortezomib for vincristine in R-CHOP could imp...
Author: feeds
Added: 06/30/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 30, 2015 Category: Cancer & Oncology Source Type: podcasts
